Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial.

Saved in:
Bibliographic Details
Title: Angiotensin Receptor Neprilysin Inhibition and Cardiovascular Outcomes Across the Kidney Function Spectrum: The PARAGON-HF Trial.
Authors: Mc Causland FR; Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA. Electronic address: fmccausland@bwh.harvard.edu., Vaduganathan M; Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Claggett B; Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Gori M; Cardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy., Jhund PS; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom., McGrath MM; Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachusetts, USA., Neuen BL; George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia; Department of Renal Medicine, Royal North Shore Hospital, Sydney, New South Wales, Australia., Packer M; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, Texas, USA., Pfeffer MA; Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Rouleau JL; Institut de Cardiologie de Montréal, Université de Montréal, Montreal, Quebec, Canada., Senni M; Cardiology Division, Cardiovascular Department, Azienda Ospedaliera Papa Giovanni XXIII Hospital, Bergamo, Italy., Swedberg K; Department of Molecular and Clinical Medicine, University of Gothenburg, Sweden., Zannad F; Inserm CIC1433, CHRU de Nancy, Université de Lorraine, Nancy, France., Zile M; Medical University of South Carolina, Charleston, South Carolina, USA; Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina, USA., Lefkowitz MP; Novartis Pharmaceuticals, East Hanover, New Jersey, USA., McMurray JJV; British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom., Solomon SD; Harvard Medical School, Boston, Massachusetts, USA; Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Source: JACC. Heart failure [JACC Heart Fail] 2025 Jan; Vol. 13 (1), pp. 105-114. Date of Electronic Publication: 2024 Nov 20.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101598241 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2213-1787 (Electronic) Linking ISSN: 22131779 NLM ISO Abbreviation: JACC Heart Fail Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2213-1787
DOI:10.1016/j.jchf.2024.08.022